A Study of S-892216 in Participants With COVID-19

Completed · Phase 2 · Has a placebo group

Conditions studied: COVID-19

In brief

The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Key facts

Study ID
NCT06928051
Run by
Shionogi
People needed
282
Starts
2025-06-06
Expected to finish
2025-09-22
Last updated by the study team
2025-09-30

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.